---
title: "Novo Nordisk's weekly diabetes medications see new progress in national insurance coverage, supporting long-term management for patients"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/45075157.md"
description: "On November 14, the &#34;National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog (2026)&#34; (hereinafter referred to as the 'New National Healthcare Security Administration Catalog') was officially released. Novo Nordisk's Tresiba FlexTouch (insulin degludec/liraglutide), the world's first and currently only * approved once-weekly combination of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been successfully included in the new catalog. The medical insurance payment scope covers adult patients with type 2 diabetes who have inadequate glycemic control after treatment with basal insulin or GLP-1 receptor agonists..."
datetime: "2026-11-14T12:47:10.000Z"
locales:
  - [en](https://longbridge.com/en/topics/45075157.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/45075157.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/45075157.md)
author: "[推医汇](https://longbridge.com/en/profiles/12109496.md)"
generator: "portal-rs"
---

# Novo Nordisk's weekly diabetes medications see new progress in national insurance coverage, supporting long-term management for patients

On November 14, the 'National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog (2026)' (hereinafter referred to as the 'New National Healthcare Security Administration Catalog') was officially released. Novo Nordisk's Novoject® (icodec insulin + semaglutide injection), the world's first and currently only \* approved once-weekly combination of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been successfully included in the new catalog. The reimbursement scope covers adult patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control despite treatment with basal insulin or GLP-1 receptor agonists. Novoject® achieved a significant price reduction through the national healthcare security administration negotiation, substantially lowering the economic burden on patients and enabling more Chinese adults with T2DM to benefit from this innovative therapy. The new catalog will officially take effect on January 1, 2027.

To ensure that improved accessibility driven by healthcare security administration entry benefits patients sooner, Novo Nordisk announced on the same day that it would progressively declare price reductions for Novoject®'s provincial listing prices starting November 15, bringing out-of-pocket costs down to the healthcare security administration price level as early as possible. This means that before the new catalog takes effect on January 1, 2027, patients can gradually enjoy the actual financial relief brought by price reductions as local listing processes advance.

Dr. Cai Yan, Senior Vice President of Global Operations and President of Greater China at Novo Nordisk, stated: 'Novoject® is another important outcome of Novo Nordisk’s 'Co-Creation in China' initiative. The successful inclusion in the national healthcare security administration catalog makes China the first country globally to achieve reimbursement for Novoject®, accelerating the translation of 'Co-Creation in China' outcomes into tangible healthcare security benefits for Chinese T2DM patients. Diabetes treatment has entered the era of once-weekly formulations, bringing not just a change in injection frequency, but a tangible improvement in patients' lives by reducing hundreds of annual injections.' 

Currently, approximately 148 million adults in China have diabetes. For many T2DM patients, daily injections still represent a dual physical and psychological burden. With advancements in relevant clinical research, the management philosophy for T2DM has gradually shifted from 'glycemia-centric' to 'patient-centric'. Treatment plans now require comprehensive consideration of glycemic efficacy, safety, and adherence.

Novoject® combines icodec insulin, the world's first once-weekly basal insulin, with semaglutide, a widely used once-weekly GLP-1 RA. Clinical studies show that Novoject® improves glycemic 达标 rates while addressing clinical management needs such as reducing hypoglycemia risk and promoting weight loss. Once-weekly dosing significantly reduces the injection burden on patients.

Another once-weekly glucose-lowering agent, Icodec insulin (brand name: Novoject®), successfully renewed its contract, expanding the reimbursement scope to 'patients with type 2 diabetes', further supporting more Chinese T2DM patients to initiate once-weekly insulin therapy promptly.

**About Icodec Insulin and Semaglutide Injection (Brand Name: Novoject®)**

Icodec insulin and semaglutide injection integrates the once-weekly basal insulin icodec insulin and the once-weekly GLP-1 RA semaglutide into a single formulation. Through mechanism complementarity, it achieves synergistic effects, simplifying treatment regimens while significantly enhancing patient satisfaction, vividly embodying the 'patient-centric' treatment philosophy. Compared to basal insulin alone, icodec insulin and semaglutide injection offers a novel therapeutic option for T2DM patients with inadequate glycemic control. It improves glycemic control and HbA1c 达标 rates, delivers significant weight loss benefits, carries a significantly lower risk of hypoglycemia, reduces insulin dosage, and simplifies treatment regimens, providing Chinese adult T2DM patients with an innovative solution that balances efficacy, safety, and convenience, helping them return to a simple and relaxed life.

**About Icodec Insulin (Brand Name: Novoject®)**

Icodec insulin injection is the world's first once-weekly basal insulin launched in China in 2024. This product features innovation, efficacy, safety, and cost-effectiveness: its glycemic-lowering effects and safety 达标 rates are superior to those of daily basal insulin formulations. Injected once weekly, it improves patient adherence compared to daily basal insulin, reduces total medical costs, and is recommended by the 'Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition)'. It fully embodies the 'patient-centric' treatment philosophy.

**About Novo Nordisk**

Novo Nordisk is a global healthcare company committed to 'Healthier Future Starts Now'. For over a century, we have consistently combined leading scientific expertise with deep insights into people's lives. We develop innovative therapies and provide related support to help millions achieve visible, tangible, and long-lasting health improvements that extend into the future. Every day, over 67,000 employees worldwide work together to fulfill our mission, driving change and co-creating a healthier future. Through collaborations, various projects, and strategic investments, we are dedicated to preventing diseases, expanding access to treatments, and reducing environmental impact, helping more people live healthier lives.

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**